1 INTRODUCTION

Liver embryonic development occurs within endodermal lineages. During gastrulation, mesendoderm arises, from which definitive endoderm is specified through the combined action of Nodal and BMP signalling. Subsequently, the embryonic liver bud arises from the ventral region of the anterior foregut after exposure to inductive signals from adjacent cardiac mesoderm, and within the liver bud, a population of bipotent hepatic progenitor cells (HPCs, also called hepatoblasts) is specified. HPCs are able to differentiate into either hepatocytes or cholangiocytes (biliary epithelial cells).1-3 HPCs express both α-fetoprotein and albumin (ALB), markers of hepatocytes.
and also CK7 and CK19, markers of cholangiocytes. During HPC differentiation to hepatocytes, CK19 expression is quickly lost followed by loss of CK7, but the expression of both CK7 and CK19 is retained as they differentiate to mature cholangiocytes. Biliary flow occurs in channels between hepatocytes in the liver sinusoid (Canals of Hering) then enters the biliary tree which is lined with cholangiocytes that express both cytokeratins CK7 and CK19. CK7 and CK19 are not expressed by mature hepatocytes.

The investigation of developmental mechanisms leading to terminally differentiated hepatocytes has been hampered by deficiencies in the culture of primary hepatocytes, which rapidly lose their metabolic activity during cell culture. Though key liver developmental pathways have also been informed by studies of differentiating pluripotent stem cells, these fail to yield fully mature hepatocytes with full metabolic activity in vitro. However, a cell line called HepaRG is useful because it can be differentiated in vitro to yield metabolically active hepatocytes and cholangiocytes, and the differentiation of HepaRG cells to hepatocytes and cholangiocytes is simpler than the directed differentiation of human pluripotent cells. Differentiated HepaRG cultures develop 3-dimensional hepatocyte colonies that express both phase I (cytochrome P450) and phase II (xenobiotic conjugating) drug-metabolizing enzymes, hepatic nuclear receptors and transporter proteins and are thus similar to primary hepatocytes. Hepatocyte colonies are surrounded by a monolayer of cholangiocytes in differentiated HepaRG cultures. The bipotentiality and full metabolic activity of HepaRG cells therefore render this cell line a useful model in which to study hepatic bipotency, in addition to its widely recognized uses in pharmacological and toxicological research.

Long non-coding RNAs (lncRNAs) are a set of highly diverse transcripts present in all mammalian cells that participate in a wide range of molecular and cellular regulatory mechanisms. The human genome contains over 20,000 genes that encode proteins. However, the human genome is pervasively transcribed at low levels. It is now clear that much of the transcribed genome leads to the production of lncRNAs, which far outnumber mRNAs. lncRNA transcription and processing are similar to that of mRNAs, being transcribed by RNA polymerase II, subject to intron-splicing and polyadenylation, though lncRNAs have a significant bias for being composed of two exons and are typically expressed at levels lower than that of mRNAs. lncRNAs vary in length from 200 nucleotides to over 50 kilobases. The functions of lncRNAs are diverse. At the level of molecular epigenetics, many lncRNAs are involved in the regulation of protein-coding genes, often via the recruitment of chromatin remodelling factors, chromatin reader proteins or silencing factors that serve to establish active or repressed transcriptional states upon individual genes. lncRNAs participate in the regulation of major cellular events including cell proliferation, the maintenance of stem cell pluripotency and differentiation. lncRNAs also function in stem cell renewal, differentiation and cellular reprogramming. lncRNA RoR (regulator of reprogramming), along with other lncRNAs, participates in the generation of induced pluripotent stem cells. Only a small proportion of the tens of thousands of likely lncRNAs have been studied in detail.

Recent advances show that lncRNAs are intimately involved in key aspects of normal liver function, development, regeneration and disorders of the liver. The lncRNA-LALR1 (lncRNA associated with liver regeneration) increases hepatocyte proliferation after partial hepatectomy by triggering responses in the Wnt/β-catenin pathway leading to cyclin D1 expression. The lncRNA CUDR (cancer upregulated drug resistant) enhances differentiation of embryonic stem cells into hepatocyte-like cells, and overexpression of CUDR induces liver stem cells to undergo malignant transformation. In addition, a great number of lncRNAs have recently been shown to be dysregulated in hepatocellular carcinoma. lncRNAs have also been implicated in liver fibrosis, dyslipidaemias and steatohepatitis.

We were intrigued by the recent discovery of a human lncRNA called APOA1-AS, an antisense lncRNA that regulates the neighbouring APOA1 gene within the 11q23.3 apolipoprotein gene cluster. We became interested in other potential lncRNAs in this cluster, hypothesizing that they might also be primarily involved in apolipoprotein gene regulation. To our surprise, we found a novel lncRNA with a prominent role in the regulation of differentiation of HPCs to hepatocytes and cholangiocytes using the bipotent HepaRG cell line as a model system. Here, we describe the discovery and analysis of a novel lncRNA that we have dubbed Inc-RHL (regulator of hepatic lineage) which regulates the differentiation of bipotent HepaRG cells to hepatocytes and cholangiocytes.

# MATERIALS AND METHODS

## 2.1 Tissue and cell culture

Frozen liver biopsies were procured from the Liver Tissue Cell Distribution System, University of Minnesota. Two media were used for HepaRG culture: HepaRG growth medium was prepared by adding HepaRG growth Supplement (Lonza, cat# ADD711C) to 500 ml of William’s E medium (Thermo Fisher Scientific). HepaRG differentiation medium was prepared by adding HepaRG Differentiation Supplement (Lonza, cat# ADD721C) to 500 ml of William’s E medium. Both were supplemented with 2 mM Glutamax and antibiotics (100 units/ml penicillin G sodium, 100 µg/mL streptomycin sulhate). For the expansion phase of HepaRG culture, HepaRG cells (1.5 × 10⁶) were plated in a T25 collagen-coated flask in HepaRG growth medium for 14 days. Differentiation of HepaRG cells was induced by adding HepaRG differentiation media and growth media (in a 1:1 ratio) from days 15 to 20, then pure HepaRG differentiation medium until day 33. Medium was changed every 2-3 days. HepG2 cells were cultured in Dulbecco’s modified eagle medium (DMEM) containing 1gm/L glucose and 10% foetal bovine serum (FBS) (Atlanta Biologicals, #S10250H). All cell lines were maintained at 37°C in humidified incubators with 5% CO₂.
2.2 | RACE PCR

RACE PCR was performed using a Clontech SMARTer RACE 5’/3’ Kit (cat. # 634 858). Gene-specific primers (Table S1) were obtained from Invitrogen (Life Technologies). RACE was performed as follows: total RNA was isolated from HepG2 cells using NucleoSpin RNA Plus Kit (cat. # 740 984.50; Macherey-Nagel). mRNA integrity was determined using an Agilent 2100 Bioanalyzer System. 5’ and 3’ RACE ready cDNA was synthesized using the SMARTer RACE 5’/3’ Kit according to the manufacturer’s protocol. 5’ and 3’ RACE ready cDNA was amplified by PCR using 5’ and 3’ gene-specific primers 5’ RACE and 3’ RACE (Table S1) and the long universal primer (provided in the kit), which was used as the second primer for both 5’ and 3’ RACE PCRs. 25 µl of the initial 5’ and 3’ RACE PCR products was used as a template for 5’ and 3’ nested PCR using the primers nested 5’ RACE and nested 3’ RACE (Table S1). Nested PCR was performed using 5’ and 3’ RACE gene-specific primers and the short universal primer (provided in the kit). The amplified RACE products were extracted from agarose gels using the NucleoSpin Gel and PCR Clean-up Kit (cat. # 740 609.50). The 5’ and 3’ RACE products were cloned into a linearized pUC-19-based vector (Clontech) and cloned using an In-Fusion HD Cloning Kit (provided in the SMARTer RACE kit). Plasmid DNA was isolated by Qiagen QIAprep Spin Miniprep Kit. Cloned products were sequenced using M13 forward and reverse primers.

2.3 | Production of stable shRNA Inc-RHL knockout cells

Packaged lentivirus containing 3 shRNAs designed to target Inc-RHL (based on our complete Inc-RHL sequence) was procured from transOMIC Inc. and expressed from a pZIP-inducible lentiviral vector as well as a non-targeting scrambled control shRNA. Stable Inc-RHL shRNA and scrambled control HepaRG cell lines were generated by transducing the lentiviral particles per the manufacter’s protocol. Briefly, HepaRG cells were seeded to 50% confluency and cultured for 24 hours in HepaRG growth medium before transduction in a 6-well plate. HepaRG cells were transduced with the lentiviral shRNA in a mixture of polybrene 8.5 µg/ml (TR-1003, Sigma-Aldrich, USA) in complete HepaRG growth medium for 24 hours. Medium was then changed to HepaRG growth medium for an additional 48 hours. Growth medium was supplemented with puromycin (2.5 µg/ml) (Sigma-Aldrich) for all subsequent culture. All inducible shRNA knockdown experiments were performed using HepaRG cells of passage 17-20. Induction of shRNA inserts was performed by adding doxycycline (1.5 µg/ml). Fresh media with doxycycline was replaced every 24 hours since the half-life of doxycycline in media is 24 hours.

2.4 | RT-PCR

RT-PCR for Inc-RHL was performed using Taq 2X master mix (M0270L) purchased from New England Biolabs, using primers described in Table S1. The amplified RT-PCR products were run on 10% DNA polyacrylamide gel and visualized through a UV transilluminator.

2.5 | Quantitative Real-time Reverse Transcriptase-Polymerase Chain Reaction (qRT-PCR)

Total RNA was isolated from HepaRG cells using the NucleoSpin RNA Plus Kit according to the manufacturer’s protocol (Macherey-Nagel). RNA samples were treated with RNase free DNase I (cat. # 18047019—Thermo Fisher Scientific). Total RNA was then used for first-strand cDNA synthesis by an iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). Primers (Table S1) were designed using PrimerQuest tool™ (Integrated DNA Technologies) and purchased from Invitrogen (Life Technologies, Carlsbad, CA, USA). cDNA was synthesized from total RNA using iScript Green reagents, and an ABI 7500 Fast Real-Time PCR system (Applied Biosystems, Carlsbad, CA). Gene expression was quantified by the 2^ΔΔCT method and normalized to β-actin mRNA expression.

2.6 | Statistical analysis

All data were analysed by GraphPad Prism software (GraphPad Software, Inc, La Jolla, CA, USA). A one-way ANOVA was performed followed by a post hoc Tukey-Kramer test with multiple comparisons to determine significant gene expression changes. One asterisk represents a p-value less than 0.05, two asterisks represent a P-value less than .01, and three asterisks represent a P-value less than .001.

3 | RESULTS

3.1 | Discovery and basic characterization of Inc-RHL

We were intrigued by the recent discovery of a human IncRNA called APOA1-AS that regulates the neighbouring APOA1 gene within the 11q23.3 apolipoprotein gene cluster.34 We investigated the entire 11q23.3 cluster for its potential IncRNA content using non-coding RNA annotations (UCSC and ENSEMBL genome browsers) and epigenome databases (ENCODE). We identified a potential IncRNA (ID: TCONS_00019176) which overlapped a stretch of H3K36 histone methylation (a chromatin marker of transcribed regions). Based on functional experiments (described below), we dubbed this RNA ‘Inc-RHL’ (IncRNA regulator of hepatic lineages). The annotated length of RNAseq reads was 333 bases, flanked at the 5’ end by APOA4 and at the 3’ end by APOA5 genes (Figure 1). Annotations suggested a single 462-base intron. We next sought to experimentally determine
whether lnc-RHL was transcribed and detectable as a spliced RNA in cells of hepatic origin. We prepared total RNA from 3 normal human liver samples and HepG2 cells (a hepatocellular carcinoma cell line) to see whether lnc-RHL could be detected as a spliced RNA by RT-PCR. We designed RT-PCR primers to span the predicted intron (Figure 2A), reasoning that if an RT-PCR product of 258 bp was detected, that this is strong evidence of a transcribed and spliced RNA species. RT-PCR was performed using DNase1-treated RNA (to remove contaminating genomic DNA), and we observed the expected 258-bp product in all samples (Figure 2B). Browser-based expression data showed lnc-RHL is expressed in liver and testes, with negligible expression in other organs (Figure 2C) a finding also confirmed by perusal of the Genotype-Tissue Expression Project (GTEx; data not shown).

We next performed rapid amplification of cDNA ends (RACE) to precisely ascertain the structure of lnc-RHL. First, we amplified lnc-RHL–specific cDNA using primers designed to anneal to lnc-RHL within the annotated 333-base sequence and universal RACE primers to yield 5' and 3' RACE products. Initial 5' and 3' RACE products yielded a faint smear of cDNA (not shown), so a second RACE amplification was performed using nested lnc-RHL–specific primers and the same universal RACE primers. This strategy yielded crisp 5' (~300 bp) and 3' (~650 bp) RACE products (Figure 2D). We cloned these into a pRACE vector and sequenced five independent clones of each. All five 5' clones had identical sequence, and all five 3' clones were identical, except for the length of a poly-A tail of about 20 nucleotides. We subjected the lnc-RHL sequence to the program Poly(A) Signal Miner35 and found a canonical AATAAA polyadenylation signal sequence 15 nucleotides from the 3' end, a typical position.36 We subjected the assembled full-length cDNA sequence to an NCBI BLAST search and found that 5' and 3' RACE sequences overlapped and mapped to human chromosome 11q23.3 as expected. The full-length sequence of lnc-RHL was determined to be 670 bases (excluding the poly-A tail) (Figure S1). Our RACE analyses showed that there are additional 5' and 3' sequences present in exons 1 and 2 of lnc-RHL that were not annotated in public RNAseq reads, which spanned only 333 bases. The Inc-RHL gene is interrupted by a single intron of 462 bp.

We then subjected the 670-bp Inc-RHL sequence to a battery of informatic analyses. We first assessed Inc-RHL for the presence of open reading frames (ORFs) and found two very short ORFs of 30 and 29 codons (Figure S2). Predicted peptide sequences were used to query the UniProtKB and Swiss-Port databases but no similarities to known proteins were found. We also subjected the full Inc-RHL sequence to the Coding Potential Calculator 2 (CPC2) program37 (Figure 2E). A score of less than 0 is predictive of a non-coding RNA. The coding potential score of Inc-RHL was −1.28949, lower than that of H19 (a well-studied IncRNA) and much lower than two protein-coding mRNAs (GAPDH and APOA1). We also subjected the Inc-RHL sequence to analysis by other programs including NCBI ORF finder, Coding Potential Assessment Tool (CPAT)38 and Lncincident39 all of which suggested that Inc-RHL is most likely a non-coding IncRNA and is unlikely to encode a functional protein. We conclude that the 670 base Inc-RHL is very likely a non-coding IncRNA based on these analyses. Most IncRNAs contain degenerate transposable elements.20,40,41 We therefore queried two programs (Repeat masker and DFam). Repeat masker identified a stretch of 373 bp (nucleotides 125-497 of Inc-RHL) that aligned with an ERVL-MaLR retrotransposon long terminal repeat (LTR) (Figure S1A). Inc-RHL sequence shares a region of conservation with the ERVL-MaLR element over 56% of its length, though with dozens of divergent nucleotide changes and 4 gaps suggesting the presence of an ancestral element. We also found an 86-nucleotide region near the 3' end of the Inc-RHL gene similar to a CR1 transposable element, subfamily class L3, but this is located on the

![FIGURE 1](image-url)
opposite, untranscribed strand of the Inc-RHL gene. We also determined a predicted secondary structure of Inc-RHL using the folding algorithm Vienna (Figure S3A). This program identified predicted regions of internal base pairing and unpaired loops based on an algorithm in which the most likely secondary structures are chosen based on minimization of molecular free energy (Figure S3B).
3.2 | Kinetics of Inc-RHL, APO and hepatocyte/cholangiocyte marker expression during HepaRG differentiation

Bipotent HepaRG cells differentiate into both hepatocytes and cholangiocytes using an established differentiation protocol (Figure 3A, Materials and Methods). Briefly, HepaRG cells were first expanded and then induced to differentiate by medium composition changes. Inc-RHL was barely detectable by RT-PCR in undifferentiated cells, but was robustly upregulated in differentiated cultures (Figure 3B). Similar to previous reports,7-9,42 we found that cultures developed 3-dimensional colonies of hepatocytes residing on a monolayer of cholangiocytes after differentiation was completed (Figure 3C).

We also assessed levels of Inc-RHL and relevant marker gene expression before and after differentiation using qRT-PCR (Figure 4). Inc-RHL was upregulated about sevenfold after differentiation, while the primitive hepatoblast marker α-fetoprotein (AFP) was reduced after differentiation. The definitive hepatocyte markers albumin and HNF4α were significantly upregulated upon differentiation. 11q23.3 mRNAs encoding hepatically expressed apolipoproteins (APOA1, APOC3 and APOA5) were negligibly expressed in undifferentiated HepaRG cells but sharply induced by differentiation.

**FIGURE 3** Differentiation of bipotent HepaRG cells to hepatocytes and cholangiocytes and differentiation-induced expression of Inc-RHL. A, Undifferentiated HepaRG cells are expanded in growth medium for 14 days yielding bipotent cells, then grown in differentiation medium for an additional 14 days, yielding mixed cultures of both hepatocytes and cholangiocytes. B, RT-PCR assays from independent cultures (triplicate) at day 14 (undifferentiated) and day 33 (differentiated). Note robust induction of Inc-RHL expression upon differentiation. C, Morphology of HepaRG cultures at day 14 (undifferentiated) and day 33 (differentiated). Note that day 33 cultures consist of a monolayer of cholangiocytes upon which 3-dimensional colonies of hepatocytes occur.
APOA4, expressed primarily in intestinal enterocytes, exhibited little or no expression in HepaRG cells (data not shown). We also assessed the expression of cholangiocyte cytokeratin markers before and after differentiation. CK7 and CK19 are known markers of bipotent progenitor cells in vivo, and upon differentiation, cholangiocytes retain expression of these cytokeratins, while hepatocytes lose their expression. We found similar levels of CK7 and CK19 in undifferentiated HepaRG cultures. Levels of CK19 were increased about twofold after differentiation. We also found no difference in the expression of ZPR1 (a non-APO gene of the 11q23.3 cluster) in undifferentiated as compared to differentiated HepaRG cells.

3.3 | Functional requirement for Inc-RHL for hepatocyte differentiation and survival

To do this, we expressed Inc-RHL-specific shRNAs from an inducible lentiviral vector to allow the protracted knockdown of Inc-RHL during the entire course of differentiation or after differentiation was complete. We transduced undifferentiated HepaRG cells with a set of three lentivirus preparations (called sh-A, sh-B and sh-C) each harbouring a doxycycline (Dox)-inducible shRNA predicted to target Inc-RHL (Figure S4). In pilot experiments, we found that sh-B and sh-C robustly knocked down Inc-RHL, while sh-A achieved only a moderate knockdown. These stably integrating viral sequences are selectable with puromycin and simultaneously express both GFP and the shRNA upon Dox induction. Once stably transduced HepaRG cells were transduced and selected with puromycin, we performed a set of three related experiments (Figure 5A): Experiment 1 was a no-Dox control, in which all 4 cell types (untransduced cells and cells transduced with scrambled, sh-B, and sh-C) were expanded for 14 days in the absence of Dox, then differentiated for an additional 19 days in the absence of Dox. Experiment 2 was conducted by expanding and differentiating cells in the absence of Dox and then adding Dox for the final 3 days of culture (Dox induction after...
differentiation). Experiment 3 was conducted by adding Dox during the entire course of the differentiation phase of cell culture (Dox induction concurrent with differentiation). For these experiments, we used non-clonal batches of HepaRG cells transduced with each construct and maintained them under continued selection as a strategy to mitigate the effects of varying lentiviral integration sites.

All transduced HepaRG cells expressed GFP upon Dox induction, and GFP expression was not detected in the absence of Dox (Figure 5B,C). In the HepaRG cells without virus, those harbouring the scrambled virus or harbouring sh-B or sh-C (without Dox-induced knockdown of Inc-RHL), we observed dense colonies of hepatocytes interspersed between a monolayer of cholangiocytes (Figure 5B,C). However, we noted a striking reduction in the number and size of hepatocyte colonies in cells harbouring sh-B or sh-C when shRNAs were induced by Dox, both under conditions of terminal (after differentiation) knockdown, and in cells in which Inc-RHL was continuously knocked down during differentiation (Figure 5C). This phenotype of hepatocyte colony failure was robust for Dox-induced cultures
harbouring sh-B and sh-C, but slightly more pronounced with sh-C. Using a flow cytometry assay, we found that a high proportion of cells expressed GFP (a reporter of knockdown) after Dox induction, including 98.1% of cells subjected to Dox induction over the entire course of differentiation (days 14-33) and 91.5% of cells induced with Dox during the final three days of differentiation (Figure S5). To quantify the hepatocyte colony failure phenotype, we scored the areas occupied by hepatocytes in 6 microscopic fields for all conditions, using single-blinded study design (Figure S6). To do this, we randomized and deidentified microscopy images, chose 6 fields for each condition, and the perimeter of hepatocyte colonies on each field was drawn and quantitated in ImageJ by an individual not privy to the identity of the cells. The identity code was then broken, and from this analysis, we found that Dox-induced knockdown of Inc-RHL decreased the areal coverage by hepatocyte colonies by about twofold to threefold in cultures subjected to terminal Dox-induced knockdown of Inc-RHL from days 30 to 33, and by about fivefold in cultures subjected continuous Dox-induced knockdown of Inc-RHL over the entire course of differentiation from days 14 to 33.

We next assessed the impact of Inc-RHL deficiency upon the expression of relevant mRNAs including hepatocyte markers, 11q23.3 mRNAs and cholangiocyte-related mRNAs (Figure 6). First, we determined that Inc-RHL itself was knocked down to about 35% or normally expressed levels after 72 hours of shRNA induction after differentiation was complete (Experiment 2, terminal knockdown) and to about 15% or normal levels by protracted shRNA induction over the entire course of differentiation. These reductions in Inc-RHL expression were associated with several interesting changes in cell type-specific content of mRNAs. AFP normally decreases modestly during differentiation (Figure 4), but in cells made deficient for Inc-RHL (either by terminal or concurrent induction), this increase was no longer observed. In normally differentiated cells, the hepatocyte marker albumin is increased, but Inc-RHL deficiency caused a reduction in detectable ALB mRNA. A similar pattern was found for the hepatocyte-specific nuclear receptor HNF4α upon Inc-RHL knockdown. In addition, levels of APOA1 and APOC3 were severely reduced by Inc-RHL deficiency, and these are known to be expressed in hepatocytes but not cholangiocytes. Together, these results are consistent with the morphological appearance of differentiated Inc-RHL-deficient cultures, which have a marked reduction in their content of hepatocytes (Figure 5 and Figure S6). The expression of the cholangiocyte marker CK7 was subtly increased by Inc-RHL knockdown concurrent with differentiation while CK19 was modestly reduced. These results show that Inc-RHL deficiency has some effect on the expression of cytokeratins (or the proportion of cytokeratin-expressing cells) in the HepaRG model in addition to its profound effect on the production of hepatocytes.

The reduced production of hepatocytes in differentiating HepaRG cultures made deficient for Inc-RHL could be due to a defect in differentiation itself, or cell death of hepatocytes induced by Inc-RHL deficiency. We therefore assessed if Inc-RHL deficiency might induce apoptosis by performing a flow cytometry assay using Annexin-V detection (Figure S7). We found little or no detectable apoptosis among cells lacking Inc-RHL during the entirety of differentiation or in cells exposed to Inc-RHL knockdown during the final 3 days of differentiation.

4 | DISCUSSION

Several of our findings support the notion that Inc-RHL is a bona fide IncRNA: (1) Inc-RHL contains only two very short ORFs (Figure S2), and the coding score for Inc-RHL (as determined by the CPC program) is lower than that of H19 (a known IncRNA) and far lower than that of mRNAs. (2) The Inc-RHL gene contains a single intron of 462 bp and is modified by the addition of a poly-A tail. It has been reported that at least 25% of IncRNAs are spliced with two or more exons and almost all are polyadenylated. (3) Inc-RHL contains a degenerate transposable element, a feature that is prevalent in IncRNAs and probably is related to their proliferation and evolution. In a study of 9,241 human IncRNAs, degenerate transposable elements were found in 83% of IncRNAs, and transposable element-related sequences comprised a total of 42% of total IncRNA sequences. We found that 56% of Inc-RHL is conserved with a consensus ERVL-MaLR element. Another study has found that ERVL-MaLR retrotransposons are enriched twofold in free cytoplasmic IncRNAs. It is now an emerging theme that transposable element insertions drive the evolution of IncRNAs, and such insertions often supply transcriptional start and polyadenylation sites that drive IncRNA evolution.

Another finding of our research is that expression of Inc-RHL is necessary for the full production of hepatocytes from bipotent progenitor cells, yet is dispensable for the production of cholangiocytes. This might be either because hepatocytes are continuously dying as they are produced during the course of differentiation, or that Inc-RHL is functionally involved in the specification of hepatocytes during the differentiation process. We favour the latter interpretation since we found little apoptosis in cells with Inc-RHL knockdown. At present, we do not know the precise molecular mechanism that leads to this phenotype. A nearby IncRNA (APOA1-AS) was shown to regulate the expression of adjacent APO genes, especially APOA1. shRNA-induced deficiency for Inc-RHL also caused a dramatic reduction in APO gene expression, but our careful analyses showed that this apparent reduction in APO mRNAs could be attributed to hepatocyte loss, as hepatocytes but not cholangiocytes express APO genes. It is formally possible that Inc-RHL also regulates the expression of nearby genes within the 11q23.3 cluster and that expression of one or more of these genes is required for hepatocyte differentiation or survival.

ACKNOWLEDGEMENTS

This research was conducted in part by funding from the Connecticut Regenerative Medicine Research Fund Grant 11SCDI02 and a grant from the University of Connecticut SPARK Program.

CONFLICT OF INTEREST

The authors declare no conflicts in this study.
AUTHOR CONTRIBUTIONS
B. Prabhakar and T. Rasmussen designed research; B. Prabhakar, SW Lee, A. Bochanis and W. He performed experiments. J. Manautou and T. Rasmussen edited the report for intellectual content. B. Prabhakar and T. Rasmussen wrote the report, and all authors approved the final report.

DATA AVAILABILITY STATEMENT
All data generated during this study are included in this report.

ORCID
Theodore P. Rasmussen https://orcid.org/0000-0001-9450-3394

REFERENCES
1. Kuwahara R, Kofman AV, Landis CS, Swenson ES, Barendswaard E. Theise ND. The hepatic stem cell niche: identification by label-retaining cell assay. Hepatology (Baltimore, MD). 2008;47(6):1994-2002.
2. Theise ND, Saxena R, Portmann BC, et al. The canals of Hering and hepatic stem cells in humans. Hepatology (Baltimore, MD). 1999;30(6):1425-1433.
3. De Alwis N, Hudson G, Burt AD, Day CP, Chinnery PF. Human liver stem cells originate from the canals of Hering. Hepatology (Baltimore, MD). 2009;50(3):992-993.
4. Gaudio E, Carpino G, Cardinale V, Franchitto A, Onori P, Alvaro D. New insights into liver stem cells. Dig Liver Dis. 2009;41(7):455-462.
5. Desmet VJ, Van Eyken P, Sciot R. Cytokeratins for probing cell lineage relationships in developing liver. Hepatology (Baltimore, MD). 1990;12(5):1249-1251.
6. Grignon P, Rumin S, Urban S, et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A. 2002;99(24):15655-15660.
7. Andersson TB, Kanebratt KP, Kenna JG. The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human. Exp Opin Drug Metab Toxicol. 2012;8(7):909-920.
8. Dianat N, Dubois-Pot-Schneider H, Steichen C, et al. Generation of functional cholangiocyte-like cells from human pluripotent stem cells and HepaRG cells. Hepatology. 2014;60(2):700-714.
9. Guillouzo A, Corlu A, Aninat C, Glaise D, Morel F, Guguen-Guillouzo C. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem Biol Interact. 2007;168(1):66-73.
10. Nagano T, Fraser P. No-nonsense functions for long noncoding RNAs. Cell. 2011;145(2):178-186.
11. Prabhakar B, Zhong XB, Rasmussen TP. Exploiting long noncoding rnas as pharmacological targets to modulate epigenetic diseases. Yale J Biol Med. 2017;90(1):73-86.
12. Clamp M, Fry B, Kamal M, et al. Distinguishing protein-coding and noncoding genes in the human genome. Proc Natl Acad Sci U S A. 2007;104(49):19428-19433.
13. Human Genome Sequencing Consortium I. Finishing the euchromatic sequence of the human genome. Nature. 2004;431(7011):931-945.
14. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature. 2004;431(7011):931-945.
15. Consortium EP, Birney E, Stamatoyannopoulos JA, et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 2007;447(7146):799-816.
16. Carninci P, Kasukawa T, Katayama S, et al. The transcriptional landscape of the mammalian genome. Science (New York, NY). 2005;309(5740):1559-1563.
39. Han S, Liang Y, Li Y, Du W. Lncident: A Tool for Rapid Identification of Long Noncoding RNAs Utilizing Sequence Intrinsic Composition and Open Reading Frame Information. *Int J Genomics*. 2016;2016:9185496.

40. Kapusta A, Kronenberg Z, Lynch VJ, et al. Transposable elements are major contributors to the origin, diversification, and regulation of vertebrate long noncoding RNAs. *PLoS Genet*. 2013;9(4):e1003470.

41. Kelley D, Rinn J. Transposable elements reveal a stem cell-specific class of long noncoding RNAs. *Genome Biol*. 2012;13(11):R107.

42. Cerec V, Glaise D, Garnier D, et al. Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. *Hepatology*. 2007;45(4):957-967.

43. Wang F, Kohan AB, Lo CM, Liu M, Howles P, Tso P. Apolipoprotein A-IV: a protein intimately involved in metabolism. *J Lipid Res*. 2015;56(8):1403-1418.

44. Derrien T, Johnson R, Bussotti G, et al. The GENCODE v7 catalog of human long noncoding RNAs: Analysis of their gene structure, evolution, and expression. *Genome Res*. 2012;22(9):1775-1789.

45. Carlevaro-Fita J, Rahim A, Guigo R, Vardy LA, Johnson R. Cytoplasmic long noncoding RNAs are frequently bound to and degraded at ribosomes in human cells. *RNA (New York, NY)*. 2016;22(6):867-882.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

---

**How to cite this article:** Prabhakar B, Lee S, Bochanis A, He W, Manautou JE, Rasmussen TP. lnc-RHL, a novel long non-coding RNA required for the differentiation of hepatocytes from human bipotent progenitor cells. *Cell Prolif*. 2021;54:e12978. [https://doi.org/10.1111/cpr.12978](https://doi.org/10.1111/cpr.12978)